Showing 2261-2270 of 9355 results for "".
- Fish Oil With Low-Dose Isotretinoin Shows Noninferior Acne Controlhttps://practicaldermatology.com/news/fish-oil-with-low-dose-isotretinoin-shows-noninferior-acne-control/2488054/Fish oil supplementation added to low-dose isotretinoin was noninferior to isotretinoin alone for reducing acne lesions and may help preserve skin hydration and limit increases in triglyceride levels, according to findings published in the
- Organon Launches Sci-Fi Inspired Campaign to Spotlight VTAMA's First-in-Class Sciencehttps://practicaldermatology.com/news/organon-launches-sci-fi-inspired-campaign-to-spotlight-vtamas-first-in-class-science/2488034/Organon is launching a new multi-channel creative campaign for VTAMA (tapinarof) cream, 1% that draws on science fiction and space-inspired storytelling to engage dermatology clinicians and emphasize the product's novel mechanism of action. Built around the tagline, "It's not science ficti
- Adalimumab Leads Cost-Efficiency Analysis of Approved HS Biologics Across Five Countrieshttps://practicaldermatology.com/news/adalimumab-leads-cost-efficiency-analysis-of-approved-hs-biologics-across-five-countries/2488023/Adalimumab offers the most favorable balance of cost and clinical efficacy among currently approved monoclonal antibody therapies for moderate-to-severe hidradenitis suppurativa (HS), according to a new economic evaluation in JAM
- Early-Life Respiratory Infections Linked to Higher Risk of Childhood Atopic Dermatitishttps://practicaldermatology.com/news/early-life-respiratory-infections-linked-to-higher-risk-of-childhood-atopic-dermatitis/2488018/Children who experience a greater burden of respiratory infections during the first 3 years of life may face an increased risk of developing atopic dermatitis (AD), according to new research in JAMA Dermatology.
- Secondary Liquid Rhinoplasty Achieves 90%+ Patient Satisfaction: Studyhttps://practicaldermatology.com/news/secondary-liquid-rhinoplasty-achieves-90-patient-satisfaction-study/2487989/Secondary liquid rhinoplasty using hyaluronic acid dermal fillers may offer a safe and effective option for correcting postsurgical nasal contour irregularities, according to a large retrospective study published in the Aesthetic
- Analysis: Antiepileptic Drugs Linked to Nearly One-Quarter of Global SJS/TEN Caseshttps://practicaldermatology.com/news/antiepileptic-drugs-linked-to-nearly-one-quarter-of-global-sjsten-cases-meta-analysis-finds/2487988/Antiepileptic drugs (AEDs) account for nearly one-quarter of Stevens-Johnson syndrome (SJS) and toxic epidermal necrolysis (TEN) cases reported worldwide, according to a systematic review and meta-analysis in JAMA Dermatology
- Analysis: Topical Corticosteroids Effective for Select Patients With DRESS Syndromehttps://practicaldermatology.com/news/analysis-data-support-topical-corticosteroids-for-select-patients-with-dress-syndrome/2487960/Topical corticosteroids may offer comparable short-term outcomes to systemic corticosteroids for selected hospitalized patients with drug reaction with eosinophilia and systemic symptoms (DRESS) syndrome, according to a multicenter retrospective cohort study publi
- EV-Related Skin Toxic Effects Associated With Improved Survival in Urothelial Cancer: Analysishttps://practicaldermatology.com/news/ev-related-skin-toxic-effects-associated-with-improved-survival-in-urothelial-cancer/2487950/Cutaneous adverse events (cAEs) that develop during treatment with enfortumab vedotin (EV) may serve as a favorable prognostic marker in patients with locally advanced or metastatic urothelial carcinoma, according to a new study published online in
- GLP-1 Receptor Agonists Linked to Reduced Psoriasis Treatment Escalation in Type 2 Diabetics: Analysishttps://practicaldermatology.com/news/glp-1-receptor-agonists-linked-to-reduced-psoriasis-treatment-escalation-in-type-2-diabetics-analysis/2487939/Adults with psoriasis and type 2 diabetes mellitus (T2DM) treated with glucagon-like peptide-1 receptor agonists (GLP-1 RAs) were less likely to require escalation of psoriasis therapy than patients receiving most other antihyperglycemic medications, according to
- Sanofi Halts Amlitelimab Development in Atopic Dermatitishttps://practicaldermatology.com/news/sanofi-halts-amlitelimab-development-in-atopic-dermatitis/2487921/Sanofi has announced it will discontinue the clinical development of amlitelimab for moderate-to-severe atopic dermatitis (AD), ending plans to submit the investigational therapy for global regulatory review after determining it would not provide a meaningful adva